On Monday, Jefferies, a well-known financial services firm, adjusted its stance on Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company. The firm lowered its price target on the stock to $40.00 from the previous $44.00. Despite this change, Jefferies maintained a Buy rating on the shares.
The revision in the price target comes after a model update following Collegium's third-quarter results. The analyst from Jefferies expressed continued optimism about the company's pain management portfolio. This positive outlook is further supported by the potential long-term growth drivers such as Jornay PM, a treatment for Attention Deficit Hyperactivity Disorder (ADHD).
Additionally, the firm highlighted the management's sustained attention to the company's financial health, noting the pro forma leverage being kept below two times. The analyst also pointed out the company's ongoing flexibility for share repurchase opportunities.
The improving prospects for two of Collegium's products, Belbuca and Nucynta, were also noted as factors contributing to the company's underappreciated value. Loss of exclusivity (LOE) events for these drugs are seen as potentially beneficial for the company's future.
In summary, Jefferies reaffirmed its Buy rating for Collegium Pharmaceutical (TADAWUL:2070) and modestly reduced the price target from $44 to $40, while underscoring the company's robust pain portfolio and strategic financial management.
In other recent news, Collegium Pharmaceuticals reported a robust 17% increase in total revenue and an 18% rise in adjusted EBITDA year-over-year, as revealed in its Third Quarter 2024 Earnings Conference Call. The integration of Ironshore Therapeutics and its ADHD treatment, Jornay PM, is projected to significantly contribute to the company's net revenue, expected to exceed $100 million in 2024. The pain management portfolio, including Belbuca and Xtampza ER, also performed strongly.
Prescriptions for Jornay PM saw a substantial rise by 31.2%, fueled by back-to-school season demand. Collegium Pharmaceuticals also provided positive financial guidance for 2024, projecting net product revenues of $620 million to $635 million. The company's new CEO, Vikram Karnani, is expected to leverage his experience to further drive Collegium's growth.
InvestingPro Insights
Complementing Jefferies' analysis, InvestingPro data reveals some compelling insights about Collegium Pharmaceutical (NASDAQ:COLL). The company's market capitalization stands at $1.04 billion, with a price-to-earnings ratio of 11.62, suggesting a potentially undervalued stock relative to its earnings.
Collegium's financial performance appears strong, with revenue growing by 9.62% over the last twelve months to $599.25 million. The company boasts an impressive gross profit margin of 86.66%, aligning with one of the InvestingPro Tips highlighting "impressive gross profit margins." This robust profitability is further supported by an operating income margin of 36.23%.
Another InvestingPro Tip notes that "management has been aggressively buying back shares," which corroborates Jefferies' observation about the company's flexibility for share repurchases. This strategy often signals management's confidence in the company's future prospects.
It's worth noting that InvestingPro offers 7 additional tips for Collegium Pharmaceutical, providing investors with a more comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.